Navigation Links
Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
Date:10/10/2007

d Dermatology. For more information about Astellas Pharma US, Inc., please visit our website at http://www.astellas.com/us.

References

(1) Goh KP. Management of hyponatremia. Am Fam Physician.

2004;69:2387-2394.

(2) Vachharajani TJ, Zaman F, Abreo KD. Hyponatremia in critically ill

patients. J Intensive Care Med. 2003;18:3-8.


'/>"/>
SOURCE Astellas Pharma US
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
2. Inhaled Steroids Safe & Effective for Children with Asthma
3. Morning after pill effective up to five days after having unprotected sex
4. Distraction therapy found very effective in postoperative patients
5. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
6. TELITHROMYCIN - the proven effective new drug for cap
7. Foods Rich In Flavonoids Effective In Prevention Of Cough
8. Looking Towards More Effective Leukemia Treatment
9. Effectiveness of acupuncture for migraines
10. PA-824 drug effective against Tuberculosis
11. Milk Thistle Not An Effective Cure For Liver Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Patriot Scientific Corporation Announces New Director 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 3Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 2Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 3Health News:Lilly Announces the First 300-unit Vial of Insulin 2Health News:Lilly Announces the First 300-unit Vial of Insulin 3Health News:Lilly Announces the First 300-unit Vial of Insulin 4Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 2Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 3
Other Medicine News:Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 3Health News:Aerosol launches immune response in lungs to wipe out lethal infections 2Health News:Aerosol launches immune response in lungs to wipe out lethal infections 3Health News:Lymphatic vessel and lymph node function are restored with growth factor treatment 2Health News:Lymphatic vessel and lymph node function are restored with growth factor treatment 3Health News:Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008 2Health News:Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008 3Health News:Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008 4Health News:Alfacell to Host Fiscal First Quarter 2008 Financial Results Conference Call and Webcast 2Health News:Superior Dental Care Alliance Launches Maximum Advantage Program 2
Breaking Medicine Technology:ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 1Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 2Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 3Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 4Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 5Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 1Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 2Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 3Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 4Experts to Highlight Key Trends in Physician and Healthcare Executive Recruitment Leadership and Compensation 57349 1Experts to Highlight Key Trends in Physician and Healthcare Executive Recruitment Leadership and Compensation 57349 2Experts to Highlight Key Trends in Physician and Healthcare Executive Recruitment Leadership and Compensation 57349 3